Expert Q&A: Labs Must Take a Greater Role in Guiding Clinicians About Abnormal Data
Lee Fleisher, MD, advocates for clearer interpretation of test results by medical laboratory scientists
Industry Buzz-lir
Subscribe today for access to
Articles and Reports
At-Home Genetic Testing: The Good, The Bad, and The Ugly
Direct-to-consumer (DTC) genetic testing has risen in popularity in recent years—but is it all it’s cracked up to be?
Clinical Lab Education: The Role of Virtual Reality
How virtual reality technologies can support clinical laboratory education efforts and what leaders should know about implementation
LLMs and the Lab
How artificial intelligence models can help labs, clinicians, and patients communicate with one another more effectively
The Top 10 Clinical Lab Acquisitions of 2023
Seven months into the year, there were already four reported deals valued at over $1 billion in 2023, as many as in all of 2022.
Sweeping New FTC Rules Could Chill Healthcare Mergers and Acquisitions
Proposed rule would require businesses to undergo even more stringent review to secure regulatory approval for such deals.
M&A and Strategic Deals: Thermo Fisher, BD, and Quest Use M&A to Advance Post-COVID-19 Strategies
Diagnostics companies that invested heavily in COVID-19 products are relying on M&A transactions to restructure and transition.
Lab Company Layoff Ledger: First Half of 2023
In the first half of this year, US companies have cut the second-highest total of jobs since 2009, according to a recent report.
Special Report: Financial Firms Project Rapid Growth of Genetic Testing Market through 2030
The outlook of the global genetic testing market based on recent reports from five financial consulting firms.
M&A & Strategic Dealmaking: Illumina May Finally Be Ready to Unwind GRAIL Acquisition
After an eventful month in the Illumina-GRAIL saga, the story may soon be over.
M&A & Strategic Deals: Dealmaking Shows New Signs of Life but FTC Scrutiny Casts a Dark Shadow
After a significant lull, M&As in the lab diagnostics space heated up in May, with several key deals announced.
Hostile Regulatory Environment Further Chills Diagnostics Market
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.
Illumina Faces Proxy Battle Over Grail Acquisition
Carl Icahn has decided to take his beef with Illumina’s board of directors over the acquisition directly to company shareholders.
